Skip to main content
Journal cover image

CYFRA 21-1 as a prognostic and predictive marker in advanced non-small-cell lung cancer in a prospective trial: CALGB 150304.

Publication ,  Journal Article
Edelman, MJ; Hodgson, L; Rosenblatt, PY; Christenson, RH; Vokes, EE; Wang, X; Kratzke, R
Published in: J Thorac Oncol
April 2012

BACKGROUND: Cytokeratin 19 and its soluble fragment CYFRA have been studied as markers that may be associated with response to therapy and survival in non-small-cell lung cancer (NSCLC). As a prospective correlative study of Cancer and Leukemia Group B 30203, a randomized phase II trial of carboplatin/gemcitabine with eicosanoid modulators (celecoxib, zileuton, or both) in advanced NSCLC, serum CYFRA levels were obtained before and during treatment. METHODS: Serum CYFRA levels were measured at baseline and after the first cycle of treatment using an electrochemoluminescent assay. Paired specimens were available from 88 patients. The logarithms of the initial concentration and of the difference in concentrations were analyzed for association with overall survival (OS) and failure-free survival (FFS). RESULTS: Lower baseline CYFRA levels were associated with both longer OS and FFS (p < 0.0001 and p = 0.0003). In addition, larger reductions in CYFRA levels correlated with longer OS and FFS (p = 0.0255 and p = 0.0068). CONCLUSION: CYFRA and change in CYFRA were found to be reliable markers for response to chemotherapy for NSCLC; however, a precise threshold to mark response has yet to be determined.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

J Thorac Oncol

DOI

EISSN

1556-1380

Publication Date

April 2012

Volume

7

Issue

4

Start / End Page

649 / 654

Location

United States

Related Subject Headings

  • Prospective Studies
  • Prognosis
  • Oncology & Carcinogenesis
  • Neoplasm Staging
  • Middle Aged
  • Male
  • Lung Neoplasms
  • Keratin-19
  • Humans
  • Female
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Edelman, M. J., Hodgson, L., Rosenblatt, P. Y., Christenson, R. H., Vokes, E. E., Wang, X., & Kratzke, R. (2012). CYFRA 21-1 as a prognostic and predictive marker in advanced non-small-cell lung cancer in a prospective trial: CALGB 150304. J Thorac Oncol, 7(4), 649–654. https://doi.org/10.1097/JTO.0b013e31824a8db0
Edelman, Martin J., Lydia Hodgson, Paula Y. Rosenblatt, Robert H. Christenson, Everett E. Vokes, Xiaofei Wang, and Robert Kratzke. “CYFRA 21-1 as a prognostic and predictive marker in advanced non-small-cell lung cancer in a prospective trial: CALGB 150304.J Thorac Oncol 7, no. 4 (April 2012): 649–54. https://doi.org/10.1097/JTO.0b013e31824a8db0.
Edelman MJ, Hodgson L, Rosenblatt PY, Christenson RH, Vokes EE, Wang X, et al. CYFRA 21-1 as a prognostic and predictive marker in advanced non-small-cell lung cancer in a prospective trial: CALGB 150304. J Thorac Oncol. 2012 Apr;7(4):649–54.
Edelman, Martin J., et al. “CYFRA 21-1 as a prognostic and predictive marker in advanced non-small-cell lung cancer in a prospective trial: CALGB 150304.J Thorac Oncol, vol. 7, no. 4, Apr. 2012, pp. 649–54. Pubmed, doi:10.1097/JTO.0b013e31824a8db0.
Edelman MJ, Hodgson L, Rosenblatt PY, Christenson RH, Vokes EE, Wang X, Kratzke R. CYFRA 21-1 as a prognostic and predictive marker in advanced non-small-cell lung cancer in a prospective trial: CALGB 150304. J Thorac Oncol. 2012 Apr;7(4):649–654.
Journal cover image

Published In

J Thorac Oncol

DOI

EISSN

1556-1380

Publication Date

April 2012

Volume

7

Issue

4

Start / End Page

649 / 654

Location

United States

Related Subject Headings

  • Prospective Studies
  • Prognosis
  • Oncology & Carcinogenesis
  • Neoplasm Staging
  • Middle Aged
  • Male
  • Lung Neoplasms
  • Keratin-19
  • Humans
  • Female